Adverse events associated with candida infections in secukinumab treatment
Chongli Yu, Tian Ma, Nan Wu, Chengxin Li, Rui Wang · 2026
Read Adverse events associated with candida infections in secukinumab treatment by Chongli Yu, Tian Ma, Nan Wu, Chengxin Li, Rui Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13491659.txt.
Description
Chongli Yu and four co-authors mine United States adverse event reports in 2026 for yeast infections linked to secukinumab, a psoriasis drug that blocks interleukin-17A. That immune signal helps defend skin and mucous membranes against Candida, so blocking it may invite infection. The authors catalogued which infections were reported, how serious they were, and when they began.
Reports filed from 2004 to early 2025 yielded 1,075 Candida events, most in the mouth, food pipe, or genital area. Genital candidiasis showed the strongest reporting signal, and more than half of events counted as serious. Signals ran higher in women and in adults aged eighteen to sixty-four. Most events began within two to three months, pointing to close monitoring early in treatment.
Catalog record
| CREATOR | Chongli Yu, Tian Ma, Nan Wu, Chengxin Li, Rui Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51698 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |